Drug intelligence / Profile preview

Sensicold

Development stage
Unknown
Lead developer
Docventures
Modality
Small Molecules
Administration
Oral
01

Overview

Sensicold is a fixed-dose combination oral syrup developed and marketed by Docventures Pharmaceuticals for the symptomatic relief of the common cold, influenza, and allergic rhinitis. The formulation contains three active small molecule ingredients: paracetamol (acetaminophen), phenylephrine hydrochloride, and chlorpheniramine maleate. Paracetamol serves as an analgesic and antipyretic by inhibiting prostaglandin synthesis in the central nervous system. Phenylephrine hydrochloride acts as a sympathomimetic nasal decongestant by stimulating alpha-1 adrenergic receptors to induce vasoconstriction in the nasal mucosa. Chlorpheniramine maleate is a first-generation antihistamine that antagonizes H1 receptors to alleviate allergic symptoms such as sneezing, rhinorrhea, and watery eyes. The product is primarily marketed in India for both pediatric and adult use.

Brand names
Sensicold
Other names
Paracetamol + Phenylephrine + Chlorpheniramine syrup
02

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)ADRA1A (α1A)HRH1 (Histamine H1 Receptor)PGHS-1 (Prostaglandin G/H Synthase 1)

Beyond the preview

Go deeper on Sensicold.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sensicold.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call